Status Epilepticus
Conditions
Keywords
Status epilepticus, Epilepsy, Stiripentol
Brief summary
The investigators retrospectively analyzed all patients who were admitted to the Department of Neurology at Marburg University Hospital between 2013 and 2023 with a diagnosis of (super)-refractory status epilepticus and who received additional treatment of SE with STP. All patients who received STP during the SE were included, regardless of previous medication.
Detailed description
The investigators retrospectively analyzed all patients who were admitted to the Department of Neurology, University Hospital Marburg, Germany, between 2013 and 2023 with a diagnosis of status epilepticus, who received additional treatment of SE with STP. They were able to identify 25 patients who received STP as add on therapy. All these patients suffered from RSE or SRSE. Since there was no SOP or treatment algorithm available, they have listed the individual treatment regimens in Table 2. 5 of these patients were previously published in a case series (Strzelczyk et al. 2015). Treatment success was defined as continuous interruption of the SE. Descriptive statistics are reported as absolute numbers and percentages, mean ± standard deviation (SD) or median ± median absolute deviation. The study was approved by the local IRB.
Interventions
DRUGStiripentol
Sponsors
University Hospital Marburg
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* adult patients who suffered from RSE or SRSE and received STP as add on therapy.
Exclusion criteria
* children
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cessation of Status epilepticus | time to cessation of SE, normally during the first days of admission, up to one week |
| Number of participants with cessation of SE by STP | up to one week |
| Median dose of STP | From date of first admission until the date of first documented improvement of status epilepticus or severe sideeffects or termination due to lack of effect or date of death from any cause, whichever came first, assessed up to 12 months |
Secondary
| Measure | Time frame |
|---|---|
| Treatment in combination with other anti-seizure medication | From date of first admission until the date of first documented improvement of status epilepticus or severe sideeffects or termination due to lack of effect or date of death from any cause, whichever came first, assessed up to 12 months |
| Individualised order of the anti-seizure medication administered | From date of first admission until the date of first documented improvement of status epilepticus or severe sideeffects or termination due to lack of effect or date of death from any cause, whichever came first, assessed up to 12 months |
Outcome results
None listed